Equities

Fusion Antibodies PLC

FAB:LSE

Fusion Antibodies PLC

Health CareHealth Care Providers
  • Price (GBX)3.65
  • Today's Change-0.10 / -2.67%
  • Shares traded167.78k
  • 1 Year change-89.26%
  • Beta0.5279
Data delayed at least 20 minutes, as of Apr 26 2024 16:10 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Fusion Antibodies PLC's revenues fell -39.55%from 4.80m to 2.90m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 116.33% reduction in net income from a loss of 1.20m to a larger loss of 2.60m.
Gross margin-7.41%
Net profit margin-179.67%
Operating margin-191.32%
Return on assets-93.94%
Return on equity-140.93%
Return on investment-130.56%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Fusion Antibodies PLC fell by 1.85m. Cash Flow from Financing totalled 3.00k or 0.10% of revenues. In addition the company used 1.75m for operations while cash used for investing totalled 111.00k.
Cash flow per share-0.0712
Price/Cash flow per share--
Book value per share0.0245
Tangible book value per share0.0245
More ▼

Balance sheet in GBPView more

Fusion Antibodies PLC uses little debt in its capital structure as supported by a debt to capital ratio of 3.13%.
Current ratio3.26
Quick ratio2.32
Total debt/total equity0.0323
Total debt/total capital0.0313
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.